lapatinib has been researched along with tak 285 in 7 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (tak 285) | Trials (tak 285) | Recent Studies (post-2010) (tak 285) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 26 | 2 | 25 |
| Protein | Taxonomy | lapatinib (IC50) | tak 285 (IC50) |
|---|---|---|---|
| Chain A, Epidermal growth factor receptor | Homo sapiens (human) | 0.023 | |
| Chain A, Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.023 | |
| Chain A, Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.017 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 1.6902 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.0138 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 2.4 | |
| Tyrosine-protein kinase Lyn | Homo sapiens (human) | 5.2 | |
| Hepatocyte growth factor receptor | Homo sapiens (human) | 4.2 | |
| Receptor tyrosine-protein kinase erbB-3 | Homo sapiens (human) | 0.023 | |
| Tyrosine-protein kinase CSK | Homo sapiens (human) | 4.7 | |
| Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens (human) | 1.1 | |
| Dual specificity mitogen-activated protein kinase kinase 5 | Homo sapiens (human) | 5.7 | |
| Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | 0.1415 | |
| Aurora kinase B | Homo sapiens (human) | 1.7 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Aertgeerts, K; Habuka, N; Hirokawa, A; Ishikawa, T; Iwamoto, K; Jennings, A; Miki, H; Ohta, Y; Sang, BC; Skene, R; Snell, G; Sogabe, S; Tanaka, T; Yano, J; Zou, H | 1 |
| Bedair, TM; Elkamhawy, A; Farag, AK; Lee, KT; Leem, DG; Pae, AN; Roh, EJ; Viswanath, AN | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Bauer, S; Baumann, M; Becker, C; Grabe, T; Hardick, J; Hodson, L; Jeyakumar, K; Ketzer, J; Keul, M; Kirschner, T; Klövekorn, P; Lategahn, J; Müller, MP; Niggenaber, J; Rauh, D; Terheyden, S; Tumbrink, HL; Unger, A; van Otterlo, WAL; Weisner, J | 1 |
| Ding, X; Li, Y; Mao, W; Meng, X; Tang, H; Wang, X; Xie, S; Yang, H | 1 |
| Bello, M; Correa-Basurto, J; García, B; Saldaña-Rivero, L; Sánchez-Espinosa, VA | 1 |
| Martiniano, B | 1 |
7 other study(ies) available for lapatinib and tak 285
| Article | Year |
|---|---|
Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein.
Topics: Allosteric Regulation; Antineoplastic Agents; Crystallography, X-Ray; Drug Design; Enzyme Activation; ErbB Receptors; Humans; Neoplasms; Protein Kinase Inhibitors; Protein Structure, Tertiary; Receptor, ErbB-2; Receptor, ErbB-4; Structure-Activity Relationship | 2011 |
Targeting EGFR/HER2 tyrosine kinases with a new potent series of 6-substituted 4-anilinoquinazoline hybrids: Design, synthesis, kinase assay, cell-based assay, and molecular docking.
Topics: Aniline Compounds; Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Molecular Docking Simulation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Structure-Activity Relationship | 2015 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Targeting Her2-insYVMA with Covalent Inhibitors-A Focused Compound Screening and Structure-Based Design Approach.
Topics: Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Humans; Kinetics; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor, ErbB-2; Structure-Activity Relationship; Tumor Cells, Cultured | 2020 |
Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Hydroxybutyrates; Lapatinib; Molecular Dynamics Simulation; Mutation; Protein Kinase Inhibitors; Purines; Quinazolines; Receptor, ErbB-2; Staurosporine | 2016 |
Structural and energetic basis for the molecular recognition of dual synthetic vs. natural inhibitors of EGFR/HER2.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Proliferation; Dimerization; ErbB Receptors; Humans; Hydroxybutyrates; Lapatinib; Molecular Dynamics Simulation; Neoplasms; Phosphorylation; Protein Conformation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2018 |
Molecular recognition of tak-285 and lapatinib by inactive, active, and middle active-inactive HER2.
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Humans; Hydroxybutyrates; Lapatinib; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Receptor, ErbB-2 | 2021 |